Patents by Inventor Matthew MCCOURT

Matthew MCCOURT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
    Patent number: 11471499
    Abstract: The present invention provides methods for inducing regression of tumors in human subjects, the methods utilize a modified mesogenic strain of Newcastle disease virus (NDV) with modified F protein cleavage site, which is non-pathogenic to poultry (lentogenic), but exhibits oncolytic properties. The disclosed methods provide safe, effective and reliable means to induce regression of a tumor in an individual in need thereof. These methods overcome the drawbacks of using pathogenic strains of viruses for human therapy.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: October 18, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Xing Cheng, Danielle Carroll, Matthew McCourt, Mark Galinski, Hong Jin
  • COMPOSITIONS FEATURING AN ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR TREATING NEOPLASIA
    Publication number: 20200181581
    Abstract: The present invention provides methods for inducing regression of tumors in human subjects, the methods utilize a modified mesogenic strain of Newcastle disease virus (NDV) with modified F protein cleavage site, which is non-pathogenic to poultry (lentogenic), but exhibits oncolytic properties. The disclosed methods provide safe, effective and reliable means to induce regression of a tumor in an individual in need thereof. These methods overcome the drawbacks of using pathogenic strains of viruses for human therapy.
    Type: Application
    Filed: November 14, 2019
    Publication date: June 11, 2020
    Inventors: Xing CHENG, Danielle CARROLL, Matthew MCCOURT, Mark GALINSKI, Hong JIN
  • Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia
    Patent number: 10519426
    Abstract: The present invention provides methods for inducing regression of tumors in human subjects, the methods utilize a modified mesogenic strain of Newcastle disease virus (NDV) with modified F protein cleavage site, which is non-pathogenic to poultry (lentogenic), but exhibits oncolytic properties. The disclosed methods provide safe, effective and reliable means to induce regression of a tumor in an individual in need thereof. These methods overcome the drawbacks of using pathogenic strains of viruses for human therapy.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: December 31, 2019
    Assignee: MEDIMMUNE LIMITED
    Inventors: Xing Cheng, Danielle Carroll, Matthew McCourt, Mark Galinski, Hong Jin
  • COMPOSITIONS FEATURING AN ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR TREATING NEOPLASIA
    Publication number: 20160208222
    Abstract: The present invention provides methods for inducing regression of tumors in human subjects, the methods utilize a modified mesogenic strain of Newcastle disease virus (NDV) with modified F protein cleavage site, which is non-pathogenic to poultry (lentogenic), but exhibits oncolytic properties. The disclosed methods provide safe, effective and reliable means to induce regression of a tumor in an individual in need thereof. These methods overcome the drawbacks of using pathogenic strains of viruses for human therapy.
    Type: Application
    Filed: September 2, 2014
    Publication date: July 21, 2016
    Applicant: MEDIMMUNE LIMITED
    Inventors: Xing CHENG, Danielle CARROLL, Matthew MCCOURT, Mark GALINSKI, Hong JIN